Aspergillosis
refers to a category of diseases caused by the aspergillus fungus. Aspergillus
is a fungus with spores that can be found in the air but does not usually cause
illness. People with damaged lungs, a weak immune system, and allergies are
more susceptible to Aspergillus infection. Invasive Aspergillosis, non-invasive
Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary and Aspergilloma
are all common Aspergillus infections (CPA). Invasive aspergillosis is a rare
infection that mostly affects persons who are immunocompromised. Chronic
pulmonary aspergillosis is an uncommon form of pulmonary aspergillosis that
exacerbates the symptoms of respiratory diseases like asthma. CPA is predicted
to impact over 240,000 persons in Europe in 2015, according to a report
released by the European Respiratory Society (ERS).
Aspergillosis Treatment Market
Dynamics
The rising
prevalence of Aspergillosis, as well as favourable government policies, are
pushing the Aspergillosis
treatments market. According to a study published in the Journal of
Fungi in 2016, CPA affects about three million individuals worldwide, making it
a major public health issue that causes mortality and morbidity. Antifungal and
corticosteroid medications can be used to treat aspergillosis. Corticosteroid
medications are used to treat allergic bronchopulmonary aspergillosis. These
medications help to lessen inflammation and respiratory symptoms including
coughing and wheezing. Methylprednisolone, prednisolone, and prednisone are some
of the most commonly used medications. Various medications for the treatment of
Aspergillosis infection have been approved by the US Food and Drug
Administration (FDA). In 2015, the US Food and Drug Administration approved
Isavuconazonium (Astellas Pharma), a prodrug version of Isavuconazole.
Aspergillosis Treatment Market
Regional Insights
Segmented the Aspergillosis therapy market into North
America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
Because of increased government initiatives for identifying and treating
infection, the Aspergillosis treatment market in North America is projected to
keep a dominating position. The Infectious Diseases Society of America (IDSA)
released revised guidelines in 2016 for the identification and management of
Aspergillus species infections. The publication provides recommendations for
non-culture-based Aspergillus infection detection and discourages the use of
combination antifungal medication for primary care. Isavuconazole, a novel
antifungal medicine licenced by the US Food and Drug Administration in March
2015 to treat mucormycosis and aspergillosis, is also defined in the
guidelines.
Comments
Post a Comment